Received the Grand Prize for Win–Win Workplace Innovation by the Ministry of Employment and Labor (awarded by the Korea Labor Law Association)

Awarded 2025 Minister of Health and Welfare Award of Commendation for Meritorious Contribution to Healthcare Technology Commercialization (CEO Park chan sun)

Closed 5th part of Series C funding (Company K Partners, Korea Investment Partners, HLB Investment)

Initiate development effort to build an AI platform designing a novel (de novo) molecular glue

Signed a joint research agreement with LigaChem for the development of a novel immuno-oncology therapy

Registered patent of ENPP1 inhibitor (Russia 1, Canada 1)

Closed 4th part of series C funding (SolidX Co., Ltd. / SolidX (SX) No.1 Venture Investment Fund / Quantum Financing & Acquisitions LLC)

Selected for Scale-up TIPS with ENPP1 inhibitors and ULK1 degraders as assets ($810,000 over 3 years)

Obtained certificate for intellectual property management company (from Korean intellectual property office)

ENPP1 inhibitor patent registration (Australia 1)

Closed 3rd part of Series C funding
(Korea Development Bank, DSC Investment Co., Ltd./Schmidt Investment Co., Ltd./ Scale-up Partners Co., Ltd.)

Closed 2nd part of Series C funding (Korea Investment & Securities Co., Ltd./Solidus Investment Co., Ltd.)

Acquired a rating of 'TI2' in technology evaluation for investment (Ecredible Co., Ltd.)

U.S. FDA designated TXN10128 as an orphan drug for pancreatic cancer patients

Registered the domestic patent “Platform technology (LIN/TMED evaluation technology)”

Closed 1st part of Series C funding (Korea Technology Finance Corporation)

Registered patent of ENPP1 inhibitor (Korea 3, Australia 1, Russia 1)

ENPP1 inhibitor, TXN10128, Phase 1 change planning IND approved

Singed MOU with LigaChem for developing ADC and ·new small molecule anti-cancer medicine

Completed free capital increase 1,200 % (capital change $ 0.25 m → $ 3.7 m)

ENPP1 inhibitor, TXN10128, Phase 1 change planning IND submitted

Selected as Top3 biotech in 2024 Start-in-tech competition (All pick by whole judging panels)

Signed MTA with HLB Life Science Co., Ltd.

Awarded Super Gap Startup Incubation Program (DIPS 1000+) grant by the Ministry of SMEs and Startups

Singed MOU for AI-assisted novel drug development (AIGENDRUG CO., Ltd.)

Signed contract with Korea Investment & Securities Co., Ltd., as a leading investor for IPO

Presented a poster describing preclinical studies of TXN10128 at the 2023 SITC annual conference in San Diego

Closed second Series B funding round (Korea Venture Investment Corp. Well to Sea, IBK, Woori Bank, Woori Financial Capital. Hyundai Pharm. C&R Research)

Awarded Korea Drug Development Fund grant for clinical development of ENPP1 inhibitor

First patient received first dose of TXN10128

Successfully completed KDDF grant for preclinical development of ENPP1 inhibitor in advance of completion date

Officially opened phase I clinical trial of TXN10128 at Asan medical center in Seoul

Awarded Global company support program grant to acquire a molecular modeling system (Ministry of SMEs and Startups)

Applied IND for clinical development of TXN10128 was approved

Completed IND submission for clinical development of ENPP1 inhibitor, TXN10128

Signed the agreement of strategic investment with Hyundai pharmaceuticals and started collaboration for novel drug development

Selected as a company receiving matching fund from Korean venture investment

Closed first part of series B funding
(Korea investment Partners, Company K investment,
Solidus investment, Daily Partners,
Meditox venture investment)

Successfully completed Tech Incubator Program
for Startup korea grant

Launched a collaboration with HK inno.N
for novel drug development

Exchanged MOU with K-MEDI Hub

Exchanged MOU with Ahngook Pharm.

Awarded Korea Drug Development Fund grant
for ENPP1 inhibitor

Awarded ministry of science
and information communication grant

Participated in the 2022 BIOUSA conference

Awarded bioresearch data generation support grant

Awarded AI voucher support grant for ULK1 inhibitor

Awarded Korea Drug Development Fund grant
for ULK1 inhibitor

Opened animal facility (named “spleen”)

Exchanged MOU with AnaPath for pre-clinical development

Participated in the 2021 BIO-EUROPE ®

Presented poster
at the 2021 AACR-NCI-EORTC annual conference

Exchanged MOU with HK Inno.N Corp.

Completed Series A funding round
(Korea Investment Partners, Schmidt,
DSC investment, Company K investment)

Closed 2^nd angel funding round

Opened headquarter and R&D center at Gwanggyo

Certified as a corporate affiliated research institute

Certified as a venture business corporation

Awarded Tech Incubator Program
for Startup Korea (TIPS) grant.

Completed Pre-A funding round
(Korea Investment Partners, Schmidt, DSC investment)

Closed 1^ST angel funding round

Launched Txinno Bioscience inc.

Started as Incubator Team #2 of BioStar project at KIST